{"url_path":"/sec/ino/8-k/2026-05-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001193125-26-232524-index.html","accession_number":"0001193125-26-232524","cik":"0001055726","ticker":"INO","issuer_name":"INOVIO PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001193125-26-232524-index.html","primary_entity_key":"0001055726","primary_entity_name":"INOVIO PHARMACEUTICALS, INC."},"word_count":370,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn May 20, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 7, 2026 (the “Proxy Statement”).\n\nOf the 69,438,100 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) entitled to vote as of the record date, which includes shares of Common Stock issuable on conversion of outstanding shares of Series C Cumulative Convertible Preferred Stock, a total of 40,670,629 shares of Common Stock, or 58.57%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.\n\nProposal 1: The election of the following eight nominees as directors of the Company to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors are elected. The votes were cast as follows:\n\n \n\nName of Director Nominee\n\n  \nVotes For\n  \nVotes Withheld\n  \nBroker Non-Votes\n\nSimon X. Benito\n\n  \n22,312,198\n  \n1,267,180\n  \n17,091,251\n\nRoger D. Dansey, M.D.\n\n  \n22,480,244\n  \n1,099,134\n  \n17,091,251\n\nAnn C. Miller, M.D.\n\n  \n22,544,652\n  \n1,034,726\n  \n17,091,251\n\nJacqueline E. Shea, Ph.D.\n\n  \n22,560,816\n  \n1,018,562\n  \n17,091,251\n\nJay P. Shepard\n\n  \n22,468,210\n  \n1,111,168\n  \n17,091,251\n\nDavid B. Weiner, Ph.D.\n\n  \n22,666,881\n  \n912,497\n  \n17,091,251\n\nWendy L. Yarno\n\n  \n22,451,874\n  \n1,127,504\n  \n17,091,251\n\nLota S. Zoth\n\n  \n22,455,943\n  \n1,123,435\n  \n17,091,251\n\nProposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n39,329,582\n\n \n1,198,040\n \n143,007\n \n—\n\nProposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement. The votes were cast as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n21,500,999\n\n \n1,607,592\n \n470,787\n \n17,091,251\n\nProposal 4: The approval of the amendment and restatement of the Company’s Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement. The votes were cast as follows:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n21,559,350\n\n \n1,535,940\n \n484,088\n \n17,091,251"}